Houston oncology co. Iterion Therapeutics raises $17M for clinical trials
Iterion Therapeutics is investigating its lead clinical candidate, Tegavivint, in a Phase 1/2a clinical trial in patients with desmoid turmors.
Read More
Building "Bridges" Across the Bayou City!
Iterion Therapeutics is investigating its lead clinical candidate, Tegavivint, in a Phase 1/2a clinical trial in patients with desmoid turmors.
Read More